{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110862","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.808075+00:00","generated_at":"2026-05-16T20:34:07.151217+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics announces CNTY-813 T1D program; Q3 net loss $34.4M, cash $132.7M","bullets":["CNTY-813 is iPSC-derived beta islet therapy for T1D; preclinical data show reversal of diabetes in mouse models.","IND-enabling studies for CNTY-813 to start by year-end 2025; IND submission planned as early as 2026.","Q3 2025 net loss $34.4M vs $31.2M in Q3 2024; R&D expenses down to $22.5M from $27.2M.","Cash and investments $132.7M as of Sep 30, 2025; estimated cash runway into Q4 2027.","Discontinuing company-sponsored CALiPSO-1 trial; continuing CARAMEL IST with data expected Dec 5, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110862","json":"https://secwatch.observer/filing/0001104659-25-110862.json","markdown":"https://secwatch.observer/filing/0001104659-25-110862.md","text":"https://secwatch.observer/filing/0001104659-25-110862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/0001104659-25-110862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/tm2530897d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:34:07.151217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}